nach oben

Seminars in Immunopathology

Erschienen in:

01.01.2012 | Review

The procoagulant and proinflammatory plasma contact system

verfasst von: Thomas Renné

Erschienen in: Seminars in Immunopathology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The contact system is a plasma protease cascade that is initiated by coagulation factor XII activation on cardiovascular cells. The system starts procoagulant and proinflammatory reactions, via the intrinsic pathway of coagulation or the kallikrein–kinin system, respectively. The biochemistry of the contact system in vitro is well understood, however, its in vivo functions are just beginning to emerge. Data obtained in genetically engineered mice have revealed an essential function of the contact system for thrombus formation. Severe deficiency in contact system proteases impairs thrombus formation but does not reduce the hemostatic capacity of affected individuals. The system is activated by an inorganic polymer, polyphosphate that is released from activated platelets. Excessive inherited activation of the contact system causes a life-threatening swelling disorder, hereditary angioedema. Activation of the contact system by pathogens contributes to leakage in bacterial infections. Mast-cell-derived heparin triggers contact-system-mediated edema formation with implications for allergic disease states. Here we present an overview about the plasma contact system in occlusive and inflammatory disease and its contribution to health and pathology.

Mackman N (2008) Triggers, targets and treatments for thrombosis. Nature 451(7181):914–918PubMedCrossRef

Macfarlane RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202:498–499PubMedCrossRef

Colman RW (2006) Contact activation pathway: Inflammatory, fibrinolytic, anticoagulant, antiadhesive, and antiangiogenic activities. Hemostasis and Thormbosis, Basic Principles and Clinical Practice, 5 edn. Lippincott Williams & Wilkins, Philadelphia

Renne T, Gailani D, Meijers JC, Muller-Esterl W (2002) Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem 277(7):4892–4899. doi:10.1074/jbc.M105221200 PubMedCrossRef

Muller F, Renne T (2008) Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 15(5):516–521PubMedCrossRef

Renne T, Dedio J, David G, Muller-Esterl W (2000) High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 275(43):33688–33696PubMedCrossRef

Renne T, Muller-Esterl W (2001) Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett 500(1–2):36–40PubMedCrossRef

Renne T, Schuh K, Muller-Esterl W (2005) Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 175(5):3377–3385PubMed

Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL (2005) Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57(1):27–77PubMedCrossRef

10.

Raslan F, Schwarz T, Meuth SG, Austinat M, Bader M, Renne T, Roosen K, Stoll G, Siren AL, Kleinschnitz C (2010) Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood–brain barrier leakage and inflammation. J Cereb Blood Flow Metab 30(8):1477–1486. doi:10.1038/jcbfm.2010.28 PubMedCrossRef

11.

Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, Bendix I, Ifergan I, Schadock I, Mori MA, Van Horssen J, Schroter F, Smorodchenko A, Han MH, Bader M, Steinman L, Aktas O, Zipp F (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15(7):788–793. doi:10.1038/nm.1980 PubMedCrossRef

12.

Ratnoff OD, Colopy JE (1955) A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 34(4):602–613PubMedCrossRef

13.

Gailani D, Renne T (2007) The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J Thromb Haemost 5(6):1106–1112. doi:10.1111/j.1538-7836.2007.02446.x PubMedCrossRef

14.

Gailani D, Broze GJ Jr (1991) Factor XI activation in a revised model of blood coagulation. Science 253(5022):909–912PubMedCrossRef

15.

Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24(6):1015–1022, Epub 2004 Apr 1029PubMedCrossRef

16.

Pauer HU, Renne T, Hemmerlein B, Legler T, Fritzlar S, Adham I, Muller-Esterl W, Emons G, Sancken U, Engel W, Burfeind P (2004) Targeted deletion of murine coagulation factor XII gene—a model for contact phase activation in vivo. Thromb Haemost 92(3):503–508PubMed

17.

Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202(2):271–281, Epub 2005 Jul 2011PubMedCrossRef

18.

Doolittle RF (2011) Coagulation in vertebrates with a focus on evolution and inflammation. J Innate Immun 3(1):9–16. doi:10.1159/000321005 PubMedCrossRef

19.

Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T (2006) Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203(3):513–518PubMedCrossRef

20.

Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, Dickneite G, Nieswandt B (2010) Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121(13):1510–1517. doi:10.1161/CIRCULATIONAHA.109.924761 PubMedCrossRef

21.

Renne T, Gailani D (2007) Role of Factor XII in hemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther 5(4):733–741PubMedCrossRef

22.

Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T (2009) Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139(6):1143–1156. doi:10.1016/j.cell.2009.11.001 PubMedCrossRef

23.

Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renne T, Gruber A, Gailani D (2010) A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. doi:10.1182/blood-2010-02-270918

24.

Kravtsov DV, Matafonov A, Tucker EI, Sun MF, Walsh PN, Gruber A, Gailani D (2009) Factor XI contributes to thrombin generation in the absence of factor XII. Blood 114(2):452–458. doi:10.1182/blood-2009-02-203604 PubMedCrossRef

25.

Meijers JC (2009) Feedback controversy stops here. Blood 114(2):235. doi:10.1182/blood-2009-04-217117 PubMedCrossRef

26.

Ratnoff OD (1968) The demise of John Hageman. N Engl J Med 279:760–761CrossRef

27.

Girolami A, Morello M, Girolami B, Lombardi AM, Bertolo C (2005) Myocardial infarction and arterial thrombosis in severe (homozygous) FXII deficiency: no apparent causative relation. Clin Appl Thromb Hemost 11(1):49–53PubMedCrossRef

28.

Koster T, Rosendaal FR, Briet E, Vandenbroucke JP (1994) John Hageman’s factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol 87(2):422–424PubMedCrossRef

29.

Zeerleder S, Schloesser M, Redondo M, Wuillemin WA, Engel W, Furlan M, Lammle B (1999) Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency—a study on 73 subjects from 14 Swiss families. Thromb Haemost 82(4):1240–1246PubMed

30.

Seligsohn U (2009) Factor XI deficiency in humans. J Thromb Haemost 7(Suppl 1):84–87. doi:10.1111/j.1538-7836.2009.03395.x PubMedCrossRef

31.

Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U (2008) Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111(8):4113–4117PubMedCrossRef

32.

Salomon O, Zivelin A, Tamarin I, Steinberg DM, Varon D, Seligsohn U (2009) Patients with severe Factor XI deficiency have a reduced incidence of venous thromboembolism. Blood 114(22):3491A

33.

Mangal AK, Naiman SC (1980) Hageman factor deficiency and oral contraceptives. Lancet 1(8171):774PubMedCrossRef

34.

Pluthero FG, Ryan C, Williams S, Brandao LR, Kahr WH (2011) Decreased in vitro thrombin generation and clot stability in human FXII-null blood and plasma. Br J Haematol 152(1):111–112. doi:10.1111/j.1365-2141.2010.08382.x PubMedCrossRef

35.

Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C (2007) Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 5(6):1143–1148. doi:10.1111/j.1538-7836.2007.02530.x PubMedCrossRef

36.

Ghebrehiwet B, Silverberg M, Kaplan AP (1981) Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153(3):665–676PubMedCrossRef

37.

Zuraw BL (2008) Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol 100(1 Suppl 2):S13–S18PubMedCrossRef

38.

Davis AE 3rd (2008) Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 100(1 Suppl 2):S7–S12PubMedCrossRef

39.

Bork K, Barnstedt SE, Koch P, Traupe H (2000) Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356(9225):213–217PubMedCrossRef

40.

Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd (2002) Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109(8):1057–1063PubMed

41.

Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM, Agostoni A (1997) Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89(9):3213–3218PubMed

42.

Nussberger J, Cugno M, Cicardi M (2002) Bradykinin-mediated angioedema. N Engl J Med 347(8):621–622PubMedCrossRef

43.

Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, Craig T, Grant JA, Hurewitz D, Bielory L, Cartwright WE, Koleilat M, Ryan W, Schaefer O, Manning M, Patel P, Bernstein JA, Friedman RA, Wilkinson R, Tanner D, Kohler G, Gunther G, Levy R, McClellan J, Redhead J, Guss D, Heyman E, Blumenstein BA, Kalfus I, Frank MM (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363(6):513–522. doi:10.1056/NEJMoa0805538 PubMedCrossRef

44.

Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anne S, Bjorkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hebert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernandez Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363(6):532–541. doi:10.1056/NEJMoa0906393 PubMedCrossRef

45.

Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363(6):523–531. doi:10.1056/NEJMoa0905079 PubMedCrossRef

46.

Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, Stevens W, Colombo R, Renne T, Drouet C, Bork K, Nothen MM (2006) Increased activity of coagulation Factor XII (Hageman Factor) causes hereditary angioedema type III. Am J Hum Genet 79(6):1098–1104, Epub 2006 Oct 1018PubMedCrossRef

47.

Dewald G, Bork K (2006) Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343(4):1286–1289PubMedCrossRef

48.

Bork K, Kleist R, Hardt J, Witzke G (2009) Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis 20(5):325–332. doi:10.1097/MBC.0b013e32832811f8 PubMedCrossRef

49.

Briseid K, Hoem NO, Johannesen S, Fossum S (1991) Contact activation factors in plasma from pregnant women—increased level of an association between factor XII and kallikrein. Thromb Res 61(2):123–133PubMedCrossRef

50.

Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, Caballero T, Drouet C, Farkas H, Massot C, Nielsen EW, Ponard D, Cicardi M (2008) Disease expression in women with hereditary angioedema. Am J Obstet & Gynecol 199(5):484.e1–484.e4CrossRef

51.

Gailani D, Renne T (2007) Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 27(12):2507–2513PubMedCrossRef

52.

Proud D, Kaplan AP (1988) Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol 6:49–83PubMedCrossRef

53.

Proud D, Togias A, Naclerio RM, Crush SA, Norman PS, Lichtenstein LM (1983) Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest 72(5):1678–1685PubMedCrossRef

54.

Noga O, Brunnee T, Schaper C, Kunkel G (1999) Heparin, derived from the mast cells of human lungs is responsible for the generation of kinins in allergic reactions due to the activation of the contact system. Int Arch Allergy Immunol 120(4):310–316PubMedCrossRef

55.

Brunnee T, Reddigari SR, Shibayama Y, Kaplan AP, Silverberg M (1997) Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 27(6):653–663PubMedCrossRef

56.

Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL (1984) In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 63(6):1453–1459PubMed

57.

Marshall JS (2004) Mast-cell responses to pathogens. Nat Rev Immunol 4(10):787–799PubMedCrossRef

58.

Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8(6):478–486PubMedCrossRef

59.

Humphries DE, Wong GW, Friend DS, Gurish MF, Qiu WT, Huang C, Sharpe AH, Stevens RL (1999) Heparin is essential for the storage of specific granule proteases in mast cells. Nature 400(6746):769–772PubMedCrossRef

60.

Forsberg E, Pejler G, Ringvall M, Lunderius C, Tomasini-Johansson B, Kusche-Gullberg M, Eriksson I, Ledin J, Hellman L, Kjellen L (1999) Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme. Nature 400(6746):773–776PubMedCrossRef

61.

Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Muller-Esterl W, Wuillemin WA, Nilsson G, Renne T (2011) Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34(2):258–268. doi:10.1016/j.immuni.2011.02.008 PubMedCrossRef

62.

Kilinc E, van Oerle R, Borissoff JI, Oschatz C, Gerlofs-Nijland ME, Janssen NA, Cassee FR, Sandstrom T, Renne T, Ten Cate H, Spronk HM (2011) Factor XII activation is essential to sustain the procoagulant effects of particulate matter. J Thromb Haemost. doi:10.1111/j.1538-7836.2011.04280.x

63.

Herwald H, Morgelin M, Olsen A, Rhen M, Dahlback B, Muller-Esterl W, Bjorck L (1998) Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases. Nat Med 4(3):298–302PubMedCrossRef

64.

Persson K, Morgelin M, Lindbom L, Alm P, Bjorck L, Herwald H (2000) Severe lung lesions caused by Salmonella are prevented by inhibition of the contact system. J Exp Med 192(10):1415–1424PubMedCrossRef

65.

Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP, Feener EP (2007) Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13(2):181–188PubMedCrossRef

66.

Zuraw BL (2008) Clinical practice. Hereditary angioedema. N Engl J Med 359(10):1027–1036PubMedCrossRef

67.

Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Guglieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodcock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26(6):669–675. doi:10.1038/nbt1407 PubMedCrossRef

68.

Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358(23):2457–2467PubMedCrossRef

69.

Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB (1992) Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 267(27):19691–19697PubMed

70.

Siebeck M, Cheronis JC, Fink E, Kohl J, Spies B, Spannagl M, Jochum M, Fritz H (1994) Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 77(6):2675–2680PubMed

71.

Schwartz LB (2008) Heparin comes clean. N Engl J Med 358(23):2505–2509PubMedCrossRef

72.

Fareed J, Walenga JM, Hoppensteadt D, Huan X, Nonn R (1989) Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci 556:333–353PubMedCrossRef

73.

Wilner GD, Nossel HL, LeRoy EC (1968) Activation of Hageman factor by collagen. J Clin Invest 47(12):2608–2615PubMedCrossRef

74.

van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, Spronk HM, Watson SP, Renne T, Heemskerk JW (2009) Dual role of collagen in factor XII-dependent thrombus formation. Blood 114(4):881–890. doi:10.1182/blood-2008-07-171066 PubMedCrossRef

75.

Reininger AJ, Bernlochner I, Penz SM, Ravanat C, Smethurst P, Farndale RW, Gachet C, Brandl R, Siess W (2010) A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 55(11):1147–1158. doi:10.1016/j.jacc.2009.11.051 PubMedCrossRef

76.

Castaldi PA, Larrieu MJ, Caen J (1965) Availability of platelet Factor 3 and activation of factor XII in thrombasthenia. Nature 207(995):422–424PubMedCrossRef

77.

Walsh PN, Griffin JH (1981) Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 57(1):106–118PubMed

78.

Ruiz FA, Lea CR, Oldfield E, Docampo R (2004) Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 279(43):44250–44257PubMedCrossRef

79.

Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH (2006) Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 103(4):903–908, Epub 2006 Jan 2012PubMedCrossRef

80.

Muller F, Renne T (2011) Platelet polyphosphates: the nexus of primary and secondary hemostasis. Scand J Clin Lab Invest 71(2):82–86. doi:10.3109/00365513.2010.550312 PubMed

81.

Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarstrom P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF (2008) Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118(9):3208–3218PubMed

82.

van der Meijden PE, Heemskerk JW (2010) Polyphosphates: a link between platelet activation, intrinsic coagulation and inflammation? Expert Rev Hematol 3(3):269–272. doi:10.1586/ehm.10.26 PubMedCrossRef

Titel: The procoagulant and proinflammatory plasma contact system
verfasst von: Thomas Renné
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Seminars in Immunopathology / Ausgabe 1/2012
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-011-0288-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The procoagulant and proinflammatory plasma contact system

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Protease-activated receptor 2 signaling in inflammation

Systemic versus localized coagulation activation contributing to organ failure in critically ill patients

Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum

Protein C anticoagulant system—anti-inflammatory effects

Thrombomodulin and its role in inflammation

Coagulation and inflammation—close allies in health and disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin